Genetic Leukemia Detection Testing Market Insights by End-user (Diagnostic & Research Centers, Hospitals, Home care, Clinics)

Genetic Leukemia Detection Testing Market Dynamics

Leukemia is the most common form of cancer in children. It accounts for approximately 35% of all cancers diagnosed in children under the age of 15. The urgency to identify any prospects of leukemia, and hospitals shifting towards tests which are advanced and less time consuming are the important factors driving the genetic leukemia detection testing market.

The growing awareness about various early genetic detection tests drives the Genetic Leukemia Detection market. However, the costs of the tests and lack of awareness in the emerging regions might restrain the growth of genetic leukemia detection testing market.

Genetic Testing For Leukemia Detection

Leukemia is a genetic disease, but it isn’t hereditary. It is caused by mutations in the genes caused by lifestyle risk factors such as smoking, exposure to certain radiations or chemicals. There are various genetic testing kits available for genetic testing of leukemia. These tests are done to identify mutations in some of the following genes, namely FLT3, CEBPA, KIT, N-RAS, MLL, WT1, IDH/2, TET2, DNMT3A and ASXL1.

Get a Sample PDF Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-6733

These tests are done using fluorescence in-situ hybridization test kits, PCR test kits, and ELISA test kits. The tests are done in hospitals, diagnostic centers, clinics, research centers and some of these kits can be availed by the customers without a doctor’s prescription.

Out of the various genetic testing methodologies for leukemia, fluorescence in-situ hybridization and PCR take only a couple of days to identify the mutations whereas cytogenetic testing takes around 2-3 weeks, because it takes time for the cells to start dividing. Hence FISH and PCR are the most lucrative segments under the Genetic Leukemia Detection Testing market.

Regional Outlook for Genetic Leukemia Detection Testing Market

Though leukemia accounts for approximately 3 % of all the cancers, the prevalence for Leukemia is highest in North America, Latin America, Eastern Europe and Western Europe. China and Asia Pacific excluding Japan follow the list in terms of prevalence. Japan and Middle East and Africa stand last in the list as the prevalence is less compared to other regions of the world.

Ask to Analyst: https://www.futuremarketinsights.com/ask-question/rep-gb-6733